William Blair & Company’s Xenon Pharmaceuticals XENE Stock Holding History

William Blair & Company’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$406K	Buy	+6,730	New	+$374K	﹤0.01%	1291

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

William Blair & Company's XENE Position: Q2 2026 in Review

William Blair & Company opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 6,730 shares worth $406K. The stake represents ﹤0.01% of the portfolio and ranks #1291 among its holdings.

315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

William Blair & Company held 6,730 shares of Xenon Pharmaceuticals worth $406K as of Q2 2026.
Xenon Pharmaceuticals was a new William Blair & Company position in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1291 holding.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.